VYGRVoyager Therapeutics Inc

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a...

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +12.96% and -74.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (NASDAQ:VYGR) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-voyager-therapeutics-inc-stock...

Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Above 50-Day Moving Average - Here's What Happened...

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) CEO Alfred Sandrock sold 11,511 shares of the firm's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price...

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) CEO Alfred Sandrock sold 11,511 shares of Voyager Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an...

Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below Fifty Day Moving Average - Here's Why...

Voyager Therapeutics (NASDAQ:VYGR) CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company's tau-directed pipeline and its newer blood-brain barrier (BBB)-penetrant capsid platform. Sandrock described 2026 as "the year of tau," while also pointing to upcoming clinical...

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Investment analysts at HC Wainwright upped their Q1 2026 EPS estimates for shares of Voyager Therapeutics in a note issued to investors on Tuesday, March 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings o...